An open label, multiple dose, phase I study in healthy volunteers to determine the pharmacokinetic, safety and tolerability profiles of oxymorphone delivered from a transdermal oxymorphone patch to promote pain relief

Trial Profile

An open label, multiple dose, phase I study in healthy volunteers to determine the pharmacokinetic, safety and tolerability profiles of oxymorphone delivered from a transdermal oxymorphone patch to promote pain relief

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Oxymorphone (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms POHO32-13
  • Sponsors Phosphagenics
  • Most Recent Events

    • 11 Aug 2014 According to a Phosphagenics media release, the data generated from this and one other study (see CT profile 700247290) will be used to help design the upcoming Phase 2 study (see CT profile 700230884) and support the IND application with the FDA.
    • 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 23 Oct 2013 Status changed from recruiting to completed, as reported by a Phosphagenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top